
Vir Biotechnology Stock Falls 18% the Day After Filing for Share Sale
The preliminary prospectus was filed after the close Thursday and left the offering price and share count blank.
Vir Biotechnology, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

The preliminary prospectus was filed after the close Thursday and left the offering price and share count blank.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Nov. 3, 2026 | Vanina de Verneuil EVP, General Counsel, Corp Sec | Sold 10b5-1 plan | 2,407 | $11.10 | $26,718 |
| Nov. 2, 2026 | Vanina de Verneuil EVP, General Counsel, Corp Sec | Sold 10b5-1 plan | 1,343 | $11.33 | $15,222 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Entry into a material definitive agreement · Other events · Financial statements and exhibits
AI summary, unreviewedVir Biotechnology prices 15,000,000-share public offering at $10.00 per share for $150 million gross proceeds
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedVir Biotechnology Phase 3 ECLIPSE 1 Hits Primary Endpoint at 44% Response, Key Secondary at 79% Undetectable Virus